Navigation Links
Life-saving primary PCI rising in Stent for Life countries
Date:5/16/2012

Paris, 16 May 2012: Life saving primary percutaneous coronary intervention (PPCI) treatment is increasing in countries participating in the Stent for Life Initiative.

These achievements and other activities will be revealed at EuroPCR 2012, 15-18 May, in Paris, France. EuroPCR is the official annual meeting of the European Association for Percutaneous Cardiovascular Interventions (EAPCI), a registered branch of the European Society of Cardiology (ESC).

The Stent for Life Initiative is driving equal access to PPCI in heart attack patients across Europe. The mission is to improve the delivery of care and patient access to the life saving indications of PPCI, thereby reducing mortality and morbidity in patients suffering from acute coronary syndromes (ACS). The objective is to increase the use of PPCI to more than 70% of all ST elevation myocardial infarction (STEMI) patients, achieving PPCI rates of more than 600 per one million inhabitants a year. To do this the aim is to offer a 24/7 PCI service at all relevant facilities to cover the country population need.

"There is great progress in all Stent for Life countries where we are promoting primary PCI," says Professor Steen Kristensen (Aarhus, Denmark), Stent for Life Initiative Chair. "All countries are reporting back now that the numbers of patients treated with primary PCI, the best reperfusion therapy, is increasing."

There are two prongs to the initiative. First is to reduce delays in patients seeking treatment. That means calling an ambulance immediately when they have symptoms of a heart attack. The Stent for Life Initiative is supporting patient awareness campaigns called ACT NOW.SAVE A LIFE in several countries to promote what patients should do if they have heart attack symptoms. More information about the campaigns and their results will be available at the Stent for Life Initiative bo
'/>"/>

Contact: Marielle de la Torre
mdelatorre@escardio.org
33-049-294-3511
European Society of Cardiology
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Chemotherapy proves life-saving for some leukemia patients who fail induction therapy
2. Life-saving radio campaign launches in Burkina Faso
3. A Life-Saving Lesson That Took Decades to Learn
4. New life-saving diagnostic test for HIV patients featured in Better World Report
5. FDA clears new IMMY and University of Nevada, Reno life-saving blood test
6. Sanitation pioneer praised by African governments for life-saving work over 3 decades
7. Nearly half of women with advanced breast cancer in the US not receiving life-saving treatment
8. Genome Scans May Reveal Life-Saving Alternatives for Cancer Patients
9. FDA approval of brain aneurysm device gives Jefferson neurosurgeons another life-saving tool
10. University of Nevada, Reno, teams with IMMY to make new life-saving blood test
11. Scripps Blood & Marrow Transplant Program Celebrates 30th Anniversary of Providing Life-Saving Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... As the Mayo Clinic's 2012 published ... & Associates Nationwide Legal Services, A.P.C., comments on these ... Verduzco v. Daiichi Sankyo, Inc., Case No. 3:15-cv-159, in ... “In light of a recently filed lawsuit, Ford & ... and explore the Mayo Clinic's Benicar case study findings ...
(Date:3/5/2015)... From Oct. 5-10, Mumbai, India will serve as host to ... include the following activities:, October 5: ... 6: Conference Day 1, ending with a Fashion Show and ... with Local Entertainment and Dinner , October 8: ... , October 9-10: Textiles in India Tour (optional; ...
(Date:3/5/2015)... (PRWEB) March 06, 2015 The global digital PCR ... 2019, at CAGR of 7.8% from 2014 to 2019. , The ... at a CAGR of 7.8% from 2014 to 2019. Although the ... larger shares in the digital PCR (dPCR) and qPCR market the ... 10.7% in the forecast period. The growth of the digital PCR ...
(Date:3/5/2015)... San Diego, CA (PRWEB) March 05, 2015 ... dangerous levels of formaldehyde in low-cost laminate ... Bamboo, the leading manufacturer of eco-friendly building materials ... to customer safety by testing all their flooring ... leading emissions detection laboratory Benchmark International ...
(Date:3/5/2015)... FL (PRWEB) March 05, 2015 ... company focused on the peripheral nerve repair market, reported ... ended December 31, 2014 compared to $2.98 million in ... of its growth strategies. , “Our strong fourth ... our peripheral nerve repair products which is driving increased ...
Breaking Medicine News(10 mins):Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 2Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 3Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 4Health News:Textile Exchange Announces the 2015 Textile Sustainability Conference Dates 2Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 2Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 3Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 4Health News:With Homeowners Concerned About Formaldehyde, Cali Bamboo Puts Safety Above Bottom Line 2Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 2Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 3Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 4
... the past decade, Asia has been the preferred destination ... medical treatments. The increase is partially due to high ... and United Kingdom. Specialized treatments, surgeries and therapies are ... cost, yet with bigger perks when it comes to ...
... Amber Court ( http://www.AmberCourtAL.com ) reaffirms its ... Public Advocate Ronald K. Chen,s investigation of Wisconsin-based Assisted ... depleted their personal savings. , ... of Amber Court Assisted Living ...
... April 21 When Gundersen Lutheran Health System set out ... to 2 percent decrease that,s common at healthcare facilities. Instead, ... less than two years. That,s 9,600 metric tons of carbon ... equivalent of removing 1,631 cars from the road. The La ...
... receive Magnet re-designation.DALLAS, April 21 The American ... Baylor University Medical Center at Dallas (Baylor ... effective immediately. Fewer than six percent of hospitals ... and merely two percent of the nation,s hospitals ...
... (BRONX, NY) Recurrent and metastatic endometrial and ... have spread to other organs and typically have developed ... chemotherapy may not be able to endure more chemo. ... Yeshiva University have shown that a combination of two ...
... Blue Cross and Blue Shield of Minnesota and ... financial results for 2008. The organization reported an overall ... revenues of $8.8 billion, with $8.0 billion paid to ... deficit was the result of net realized capital losses ...
Cached Medicine News:Health News:Medical Tourism is Good Therapy for the Hotel Industry 2Health News:Medical Tourism is Good Therapy for the Hotel Industry 3Health News:Medical Tourism is Good Therapy for the Hotel Industry 4Health News:Medical Tourism is Good Therapy for the Hotel Industry 5Health News:Amber Court Assisted Living Communities Reaffirms its Commitment to Seniors on Medicaid 2Health News:Innovative Program Will Help Lead Health System to Energy Independence by 2014 2Health News:Baylor Dallas Nationally Recognized for Nursing Excellence 2Health News:New treatment shows promise against recurrent gynecologic cancers 2Health News:Blue Cross and Blue Shield of Minnesota Releases 2008 Financial Results 2
(Date:3/5/2015)... , March 5, 2015   ndd Medical Technologies ... (PFT) that employs precise ultrasound technology, announced that its ... held by the San Antonio Pulmonary Fibrosis Support Group. ... or pulmonary fibrosis (PF), as well as those suspected ... footprint of a mere 12 square inches, EasyOne Pro ...
(Date:3/5/2015)...  Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... chronic pain, today announced the appointment of several ... panel of experts will provide support for planning ... the company pipeline of novel investigational therapies to ... range of areas including opioid receptors, addiction, psychiatry, ...
(Date:3/5/2015)... , March 5, 2015  ANI Pharmaceuticals, Inc. ... that it has acquired the approved abbreviated new ... 50mg, 100mg and 150mg, previously marketed by Teva ... for this product was approximately $39 million in ... , President and CEO of ANI Pharmaceuticals, stated, ...
Breaking Medicine Technology:ndd Medical Technologies' Mobile Pulmonary Function Testing Helps Combat Pulmonary Fibrosis 2ndd Medical Technologies' Mobile Pulmonary Function Testing Helps Combat Pulmonary Fibrosis 3Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 2Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 3Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 4ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 2ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 3
... Phase III data shows significant antitumor benefit in patients ... Early data show that at eight weeks of treatment, ... patients with advanced liver cancer - New data ... better cognitive function than those taking tamoxifen - ...
... May 27 Researchers have discovered a novel molecular path ... , a disease that mainly affects women and slowly ... finding, significant because it is a first step toward developing ... the June 11, 2009, issue of the New ...
Cached Medicine Technology:Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 2Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 3Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 4Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 5Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 6Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 7Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 8Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 9Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 10Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 11Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 12Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 13Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 14Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 15Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 16Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 17Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types 18Mayo Researchers Help Discover Genetic Cause for Primary Biliary Cirrhosis 2Mayo Researchers Help Discover Genetic Cause for Primary Biliary Cirrhosis 3Mayo Researchers Help Discover Genetic Cause for Primary Biliary Cirrhosis 4
... The Finnpipette Digital offers improved ... The rounded handle, modified grippy finger ... enhance operator comfort and efficiency. Finnpipette ... with power-boosted gearing mechanism (pat. pend.) ...
The Leader in ICU Humidification., ,Available Configurations: , Gas Sampling Port, Straight Flex Tube, Poppel Flex Tube, Luer Port for Pressure, Monitoring/Secretion Removal, Special Use Devices, M...
... Since 1991 Intersurgical ... breathing filters, heat and ... oxygen therapy products, hand-held ... range of accessories and ...
The Pall High Performance HME is a high efficiency heat and moisture exchanger, indicated to protect patients against the potential risks of ventilation with dry and cold gases....
Medicine Products: